Membrane potential assay

AG Alexander Gillis
AG Arisbel B. Gondin
AK Andrea Kliewer
JS Julie Sanchez
HL Herman D. Lim
CA Claudia Alamein
PM Preeti Manandhar
MS Marina Santiago
SF Sebastian Fritzwanker
FS Frank Schmiedel
TK Timothy A. Katte
TR Tristan Reekie
NG Natasha L. Grimsey
MK Michael Kassiou
BK Barrie Kellam
CK Cornelius Krasel
MH Michelle L. Halls
MC Mark Connor
JL J. Robert Lane
SS Stefan Schulz
MC Macdonald J. Christie
MC Meritxell Canals
ask Ask a question
Favorite

MOR-mediated activation of potassium channels was assayed using a membrane-potential dye from Molecular Devices (FLIPR Membrane Potential Assay kit) as previously described (71). On the day before the experiment, HEK293-GIRK4-MOR cells were plated into clear-bottomed, black-walled 96-well plates (Corning) precoated with poly-d-lysine for cell adherence. Cells were plated in L-15 media (Gibco, Thermo Fisher Scientific) supplemented with 1% (v/v) FBS. The following day, cell medium was aspirated, and plates were treated with either 200 nM β-CNA hydrochloride (Sigma-Aldrich) or Hepes-buffered salt solution (HBSS) vehicle control for 20 min. Testing of each compound in untreated and β-CNA–treated conditions was carried out in parallel. All experiments were carried out in duplicate. Cells were washed twice with HBSS after vehicle or β-CNA treatment and incubated for 1 hour in 50% L-15 media and 50% FLIPR dye reconstituted in HBSS in a final volume of 180 μl per well. All test compounds were serially diluted in a vehicle of 1% (v/v) dimethyl sulfoxide (DMSO), bovine serum albumin (BSA; 0.1 mg/ml) in HBSS at 10× concentrations in a 96-well compound plate (Corning) such that final assay concentrations of solvent were 0.1% DMSO and BSA (0.01 mg/ml). Plates were read in a FlexStation 3 (Molecular Devices). Two-minute baselines were taken for each well before compound addition. Then, 20 μl of 10× concentrated compound was added and read for 3 min. Peak effect was calculated by taking the minimum raw fluorescence value of the postaddition measurement period, expressed as a percentage of preaddition baseline and vehicle corrected, and normalized to the maximal response to DAMGO without β-CNA treatment.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A